The following articles (labelled with PubMed ID or TBD) are for your review
||Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.
||Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents.
||Qilu Pharmaceutical Co, Ltd
||Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
||Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform.
||Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
||A quantitative analysis of kinase inhibitor selectivity.
||Discovery and development of aurora kinase inhibitors as anticancer agents.
||Vertex Pharmaceuticals (Europe) Ltd.
||Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
||Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
||Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).
||Comprehensive analysis of kinase inhibitor selectivity.
||Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.
||Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
||Martin Luther University Halle-Wittenberg
||AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
||Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
||Center for Molecular Medicine of the Austrian Academy of Sciences
||Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
||A small molecule-kinase interaction map for clinical kinase inhibitors.